Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677377 · ClinicalTrials.gov registry record · Phase 2
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
A Phase 2 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01677377 is a Phase 2 study that has completed, run by Indivior. The registered enrollment target is 45 participants.
The verdict
NCT01677377, a Phase 2 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
Interventions
- DRUG Risperidone
- DRUG RBP-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677377
The ClinicalTrials.gov registry entry for NCT01677377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT01677377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677377 about?
NCT01677377 is a clinical study titled "Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy". Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
What is the current status of trial NCT01677377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2012-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01677377?
The interventions under investigation include: Risperidone (DRUG), RBP-7000 (DRUG).
Who is sponsoring clinical trial NCT01677377?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.